New AURA Lupus Data Bode Well For Aurinia's Voclosporin In Future Phase III
Long-term data from the AURA-LV study in lupus nephritis show voclosporin is superior to standard of care, raising expectations for future Phase III success.
You may also be interested in...
Aurinia's voclosporin missed the primary endpoint of superior tolerability compared to Restasis, but hit objective secondary efficacy endpoints that that may better position it for approval in dry eye.
Some drug makers are tackling lupus R&D by focusing on a specific subset of the disease, lupus nephritis, where diagnosis is more clear cut and the clinical endpoints are more straightforward.
Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.